ENOB
Income statement / Annual
Last year (2023), Enochian Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Enochian Biosciences, Inc.'s net income was -$80.65 M.
See Enochian Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$42.77 K |
$0.00 |
| Cost of Revenue |
$0.00
|
$113.50 K
|
$123.59 K
|
$391.42 K
|
$366.27 K
|
$71.71 K
|
$18.48 K
|
$14.53 K
|
$32.67 K
|
$314.64 K
|
| Gross Profit |
-$121.86 K
|
-$113.50 K
|
-$123.59 K
|
-$391.42 K
|
-$366.27 K
|
-$71.71 K
|
-$18.48 K
|
-$14.53 K
|
$10.10 K
|
-$314.64 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.24
|
0
|
| Research and Development Expenses |
$2.71 M
|
$4.17 M
|
$8.37 M
|
$15.72 M
|
$4.69 M
|
$2.50 M
|
$616.96 K
|
$62.76 K
|
$804.19 K
|
$0.00
|
| General & Administrative Expenses |
$24.17 M
|
$15.32 M
|
$14.33 M
|
$7.56 M
|
$7.12 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$383.55 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$24.56 M
|
$15.32 M
|
$14.33 M
|
$7.56 M
|
$7.12 M
|
$8.42 M
|
$2.60 M
|
$2.32 M
|
$1.33 M
|
$2.11 M
|
| Other Expenses |
$54.37 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$81.64 M
|
$19.60 M
|
$22.83 M
|
$23.40 M
|
$11.92 M
|
$10.92 M
|
$3.22 M
|
$2.39 M
|
$2.13 M
|
$2.11 M
|
| Cost And Expenses |
$81.64 M
|
$19.60 M
|
$22.83 M
|
$23.40 M
|
$11.92 M
|
$10.99 M
|
$3.24 M
|
$2.40 M
|
$2.16 M
|
$2.43 M
|
| Interest Income |
$0.00
|
$0.00
|
$122.04 K
|
$13.18 K
|
$50.30 K
|
$73.49 K
|
$45.82 K
|
$0.00
|
$0.00
|
$5.94 K
|
| Interest Expense |
$1.01 M
|
$706.96 K
|
$372.84 K
|
$379.61 K
|
$104.28 K
|
$43.00
|
$143.26 K
|
$26.26 K
|
$2.36 K
|
$84.55 K
|
| Depreciation & Amortization |
$121.86 K
|
$113.50 K
|
$123.59 K
|
$123.53 K
|
$366.27 K
|
$71.71 K
|
$18.48 K
|
$14.53 K
|
$27.40 K
|
$45.20 K
|
| EBITDA |
-$81.52 M |
-$19.48 M |
-$22.70 M |
-$23.28 M |
-$11.51 M |
-$17.94 M |
-$5.31 M |
-$2.39 M |
-$2.17 M |
-$2.42 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-50.7
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-49.59
|
0
|
| Total Other Income/Expenses Net |
$989.12 K
|
-$1.13 M
|
$2.65 M
|
-$3.45 M
|
$507.41 K
|
-$7.03 M
|
-$3.19 M
|
$192.72 K
|
-$77.10 K
|
-$119.20 K
|
| Income Before Tax |
-$80.65 M
|
-$39.68 M
|
-$113.43 M
|
-$26.85 M
|
-$11.42 M
|
-$18.02 M
|
-$6.42 M
|
-$2.21 M
|
-$2.20 M
|
-$2.55 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-51.39
|
0
|
| Income Tax Expense |
$0.00
|
$706.96 K
|
$34.00
|
-$125.28 K
|
$104.28 K
|
$0.00
|
-$111.72 K
|
-$64.88 K
|
-$462.79 K
|
-$177.54 K
|
| Net Income |
-$80.65 M
|
-$39.68 M
|
-$113.43 M
|
-$26.72 M
|
-$11.42 M
|
-$18.02 M
|
-$6.31 M
|
-$2.14 M
|
-$1.74 M
|
-$2.37 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-40.57
|
0
|
| EPS |
-0.84 |
-0.71 |
-2.16 |
-0.57 |
-0.25 |
-0.48 |
-0.29 |
-0.17 |
-0.18 |
-0.32 |
| EPS Diluted |
-0.84 |
-0.71 |
-2.16 |
-0.57 |
-0.25 |
-0.48 |
-0.29 |
-0.17 |
-0.18 |
-0.32 |
| Weighted Average Shares Out |
$96.25 M
|
$56.27 M
|
$52.53 M
|
$47.17 M
|
$46.33 M
|
$37.55 M
|
$21.94 M
|
$12.27 M
|
$9.53 M
|
$7.50 M
|
| Weighted Average Shares Out Diluted |
$96.25 M
|
$56.27 M
|
$52.53 M
|
$47.17 M
|
$46.33 M
|
$37.55 M
|
$21.94 M
|
$12.27 M
|
$9.53 M
|
$7.50 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
